Meet the Exhibitors
Canadian Nuclear Laboratories
CNL is Canada’s premier nuclear science and technology organization and the largest national laboratory. CNL is a world leader in developing peaceful and innovative applications from nuclear technology through its expertise in physics, metallurgy, chemistry, biology and engineering.
TRIUMF is one of the world’s leading subatomic physics laboratories. It brings together dedicated physicists and interdisciplinary talent, sophisticated technical resources, and commercial partners in a way that has established the laboratory as a global model of success. Its large user community is composed of international teams of scientists, post-doctoral fellows, and graduate and undergraduate students.
TrisKem International is a leading provider of highly selective resins and accessories. Its main product line consists of a range of extraction chromatographic resins which are increasingly finding application in the production and quality control of radionuclides such as alpha emitters, Ga-67/8, Cu-64/7, Zr-89,…
Further to its range of resins TrisKem also provides selective chromatography paper (DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68,…).
TrisKem places strong focus on the development of new resins and separation methods to meet your separation needs.
Women in Nuclear Canada
Since its inception in 2004, Women in Nuclear (WiN) Canada has promoted the role of women in the Canadian nuclear and radiation related industries. WiN Canada brings women together into a supportive environment to provide opportunities to succeed through mentoring, networking, and personal development initiatives.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion.
NorthStar Medical Technologies
NorthStar Medical Technologies is committed to providing reliable radioisotope supply solutions for patient needs and clinical research, including commercial-scale Actinium-225 production for TAT applications. NorthStar’s technologies include non-uranium domestic molybdenum-99 production methods, separation chemistry systems, sterilization systems and a technology platform for potential expanded product offerings in diagnostic and therapeutic markets.